Drug intelligence / Profile preview

HM2002

Development stage: Phase 1
Lead developer: 环码生物
Modality: Long Non-coding RNA (lncRNA) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Epicardial

Overview

HM2002 is an investigational circular RNA-based therapeutic designed as a modulator of vascular endothelial growth factor (VEGF). It is being developed for the treatment of cardiovascular diseases, specifically targeting ischemic heart failure and myocardial ischemia. The drug is administered via epicardial injection during coronary artery bypass grafting (CABG) surgery. Its mechanism involves modulation of VEGF signaling pathways to promote angiogenesis and improve cardiac function in patients with ischemic heart conditions. The first-in-human clinical trial is currently in early phase 1 to assess safety, tolerability, and preliminary efficacy in this setting.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on HM2002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HM2002.

Explore the full profile